The reimbursement cut directly pressures Orthofix's largest revenue segment. Watch for further CMS changes and competitor responses. The withdrawal of three-year targets signals structural headwinds — consider reducing exposure until clarity on payer mix and volume offsets emerges.
Price Chart
Executive Summary
Orthofix disclosed that CMS updated billing requirements for non-invasive bone growth stimulators, effective May 18, 2026, following FDA reclassification to Class II. The company expects average Medicare reimbursement to decline ~10%, leading to lowered full-year 2026 guidance: net sales of $838M-$848M and non-GAAP adjusted EBITDA of $90M-$93M, with no positive free cash flow expected. The three-year financial targets are withdrawn.
Key Facts
- CMS updated billing requirements for non-invasive bone growth stimulators (HCPCS E0747, E0748, E0760) effective May 18, 2026
- Orthofix expects average Medicare reimbursement for these codes to decline by approximately 10%
- Full-year 2026 net sales guidance lowered to $838M-$848M
- Full-year 2026 non-GAAP adjusted EBITDA guidance lowered to $90M-$93M
- Company does not expect positive free cash flow for full-year 2026
- Three-year financial targets are no longer applicable
Financial Impact
Approximately 10% decline in average Medicare reimbursement for key bone growth stimulator codes; full-year 2026 net sales guided to $838M-$848M and non-GAAP adjusted EBITDA to $90M-$93M
Risk Factors
- Further CMS reimbursement reductions could worsen the outlook
- Volume declines or payer mix shifts may amplify revenue pressure
- No positive free cash flow expected in 2026, limiting financial flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-233429 |
| Document: 0001193125-26-233429-index-headers.html | 0001193125-26-233429 |
| Document: 0001193125-26-233429-index.html | 0001193125-26-233429 |
| Document: 0001193125-26-233429.txt | 0001193125-26-233429 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | Insider Buy | $9.18 $9.74 | ▲ +6.10% | ▲ +5.41% | $9.71 (+5.77%) |
Aug 20, 2026 9w ago | Insider Cluster | $10.01 $8.95 | ▼ −10.59% | ▼ −10.06% | $9.71 (−3.00%) |
Aug 5, 2026 11w ago | 8-K | $10.42 $9.38 | ▼ −9.98% | ▼ −9.38% | $9.71 (−6.81%) |
Jul 2, 2026 16w ago | 8-K | $9.94 $11.79 | ▲ +18.61% | ▲ +19.03% | $9.71 (−2.31%) |
May 21, 2026 22w ago | 8-K | $10.41 $8.90 | ▲ +14.55% | ▲ +14.89% | $9.71 (+6.72%) |
May 5, 2026 25w ago | 8-K | $12.44 $9.71 | ▼ −21.95% | ▼ −26.90% | $9.71 (−21.95%) |
Apr 29, 2026 25w ago | DEFA14A | $11.76 $9.27 | ▼ −21.17% | ▼ −26.40% | $9.71 (−17.43%) |
Apr 9, 2026 28w ago | 8-K | $12.42 $12.19 | ▼ −1.85% | ▼ −9.42% | $9.71 (−21.82%) |
Mar 10, 2026 33w ago | Insider Cluster | $12.27 $12.42 | ▲ +1.22% | ▲ +0.69% | $9.71 (−20.86%) |
Mar 5, 2026 33w ago | Insider Cluster | $12.57 $11.53 | ▲ +8.27% | ▲ +4.49% | $9.71 (+22.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers